Literature DB >> 14685779

Dendritic cell biology and cancer therapy.

Theresa L Whiteside1, Christine Odoux.   

Abstract

Dendritic cells (DCs) are nature's best antigen-presenting cells. They possess attributes that allow them to effectively fulfill the requirements for priming/activating T cells and mediating tumor-specific immune responses. In this review, emphasis is placed on those aspects of DC biology that best illustrate their usefulness in immunotherapy of cancer. Culture, maturation, and polarization conditions for human DC are discussed, as are strategies for antigen-loading of DCs and for their delivery to patients with cancer. A concise recommendation for monitoring of DC-based vaccination trails is provided.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14685779     DOI： 10.1007/s00262-003-0468-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


  16 in total

1.  Clinical reagents of GM-CSF and IFN-α induce the generation of functional chronic myeloid leukemia dendritic cells in vitro.

Authors:  Kaizhi Weng; Xiaobao Xie; Guoqiang Qiu; Weiying Gu
Journal:  Cytotechnology       Date:  2011-09-22       Impact factor: 2.058

2.  Specifically activated dendritic cells--cell-based vaccine against lymphosarcoma exhibiting multiple drug resistance phenotype.

Authors:  N L Mironova; E E Panzinskyi; N A Popova; V P Nikolin; M A Zenkova; V V Vlasov
Journal:  Dokl Biochem Biophys       Date:  2009 Sep-Oct       Impact factor: 0.788

3.  Phenotypic and functional comparison of two distinct subsets of programmable cell of monocytic origin (PCMOs)-derived dendritic cells with conventional monocyte-derived dendritic cells.

Authors:  Babak Beikzadeh; Nowruz Delirezh
Journal:  Cell Mol Immunol       Date:  2015-02-09       Impact factor: 11.530

4.  Quantitative nanostructural and single-molecule force spectroscopy biomolecular analysis of human-saliva-derived exosomes.

Authors:  Shivani Sharma; Boyd M Gillespie; Viswanathan Palanisamy; James K Gimzewski
Journal:  Langmuir       Date:  2011-11-09       Impact factor: 3.882

5.  Pemetrexed plus dendritic cells as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer who had treatment with TKI.

Authors:  Rong-Hang Hu; Sheng-Bin Shi; Jie-Lin Qi; Jing Tian; Xiao-Yong Tang; Guo-Fang Liu; Chun-Xiao Chang
Journal:  Med Oncol       Date:  2014-06-24       Impact factor: 3.064

6.  Phenotype and polarization of autologous T cells by biomaterial-treated dendritic cells.

Authors:  Jaehyung Park; Michael H Gerber; Julia E Babensee
Journal:  J Biomed Mater Res A       Date:  2014-03-25       Impact factor: 4.396

7.  DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells.

Authors:  Daejin Kim; Chien-Fu Hung; T-C Wu; Yeong-Min Park
Journal:  Vaccine       Date:  2010-09-17       Impact factor: 3.641

8.  Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.

Authors:  Manuel Nieto-Sampedro; Beatriz Valle-Argos; Diego Gómez-Nicola; Alfonso Fernández-Mayoralas; Manuel Nieto-Díaz
Journal:  Clin Med Insights Oncol       Date:  2011-09-21

9.  Generation of functionally mature dendritic cells from elutriated monocytes using polyinosinic : polycytidylic acid and soluble CD40 ligand for clinical application.

Authors:  S Kim; H O Kim; H J Kim; K Lee; H-S Kim
Journal:  Clin Exp Immunol       Date:  2008-09-08       Impact factor: 4.330

10.  Heat-shocked tumor cell lysate-pulsed dendritic cells induce effective anti-tumor immune response in vivo.

Authors:  Jian Qiu; Guo-Wei Li; Yan-Fang Sui; Hong-Ping Song; Shao-Yan Si; Wei Ge
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.